Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Intangibles: 2010-2024

Historic Intangibles for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $46.5 million.

  • Lineage Cell Therapeutics' Intangibles fell 52.07% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 52.07%. This contributed to the annual value of $46.5 million for FY2024, which is 0.05% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Intangibles stood at $46.5 million for FY2024, which was down 0.05% from $46.6 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Intangibles peaked at $66.1 million during FY2020, and registered a low of $46.5 million during FY2024.
  • In the last 3 years, Lineage Cell Therapeutics' Intangibles had a median value of $46.6 million in 2023 and averaged $53.1 million.
  • Data for Lineage Cell Therapeutics' Intangibles shows a maximum YoY dropped of 29.60% (in 2023) over the last 5 years.
  • Lineage Cell Therapeutics' Intangibles (Yearly) stood at $66.1 million in 2020, then remained steady at $66.1 million in 2021, then remained steady at $66.1 million in 2022, then declined by 29.60% to $46.6 million in 2023, then dropped by 0.05% to $46.5 million in 2024.